Status: Recruiting
Thymosin-α1 for Recurrent Implantation Failure
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Participants needed: 136
Trial details
Phase: Phase 2, Phase 3Age: 18-40Biological sex: FemaleType: InterventionalSponsor: Fakih IVF Fertility CenterUpdated: Jun 30, 2026Locations: 1
Eligibility criteria
-Women 18-40 years [+5]
Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine... [+4]